Welcome to our dedicated page for Viatris Ord Shs SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a pharmaceutical giant that sells everything from low-cost generics to complex biosimilars means digging through hundreds of pages of dense disclosures. Viatris’ global footprint, patent expiries and FDA observations make its reports challenging to navigate, especially when time-sensitive 8-K material events can appear without warning.
Stock Titan solves that problem. Our platform delivers real-time alerts and AI-powered summaries for every Viatris filing on EDGAR—so “Viatris SEC filings explained simply” is more than a promise. Open the latest “Viatris quarterly earnings report 10-Q filing” to see revenue by therapeutic segment, or scan an AI digest that highlights pricing trends and supply-chain costs. Need insider data? We surface “Viatris insider trading Form 4 transactions” instantly, linking each trade to the related news cycle. Questions like “understanding Viatris SEC documents with AI” or “Viatris executive stock transactions Form 4” are answered right on the page.
Whether you’re reviewing a “Viatris annual report 10-K simplified” for patent-loss timelines, checking a sudden “Viatris 8-K material events explained” after an FDA inspection, or comparing bonus targets inside the “Viatris proxy statement executive compensation”, our tools keep everything in one place. Key features include:
- AI summaries that translate accounting notes and litigation disclosures into clear language
- Form 4 insider alerts with context—“Viatris Form 4 insider transactions real-time”
- Auto-tagged sections for R&D spend, biosimilar approvals and global tax rates
- Side-by-side “Viatris earnings report filing analysis” across quarters
Spend less time searching and more time making informed decisions with Viatris filings distilled by Stock Titan’s AI.
Viatris Inc. (VTRS) reported Q3 2025 results with total revenues of
Year-to-date, results reflect significant non-cash charges: a goodwill impairment of
Viatris Inc. furnished an update on its latest results. The company issued a press release reporting financial results for the period ended September 30, 2025, and furnished it under Item 2.02 of an 8‑K. The information is provided as furnished, not filed, and is included as Exhibit 99.1.
The company also announced a conference call and live webcast today at 8:30 a.m. ET to review third-quarter 2025 results. Additional exhibit materials include the cover page Inline XBRL tags (Exhibit 104).
Viatris Inc. amended and restated its bylaws effective October 24, 2025, updating proxy access timing rules when the annual meeting date shifts. The company set its 2026 annual meeting for May 15, 2026.
Shareholder deadlines: Rule 14a-8 proposals are due by November 24, 2025. Proxy access nominations (up to the greater of two nominees or 20% of the Board) must be received between December 16, 2025 and January 15, 2026. Advance notice for other director nominations or business must be delivered between January 15, 2026 and February 14, 2026. Universal proxy notices under Rule 14a-19 are due by March 16, 2026.
Viatris (VTRS) filed its 2025 proxy statement calling a December 5, 2025 annual meeting in Hollywood, FL. Shareholders will vote to elect 13 directors, approve on an advisory basis 2024 compensation for named executive officers, and ratify Deloitte & Touche LLP as auditor for fiscal 2025. The record date is October 10, 2025.
The Board highlights governance changes and refreshment: an independent Chair, a planned reduction of the Board to 13 seats after the meeting, and 12 of 13 nominees deemed independent. Seven new directors have been added since December 2022. Following shareholder feedback on 2024 Say‑on‑Pay, the Board ended the Chairman Emeritus consulting arrangement effective June 30, 2025 and adjusted pay design, including cutting 2024 annual incentive funding to 140% from the formula outcome of 163.92%, raising the 2025 maximum Adjusted EBITDA hurdle to 110% of target, reducing the regulatory submissions weight to 10%, adding a 10% personal objective, and tightening share ownership rules.
Operationally, the company cites returning more than $630 million to shareholders in 1H 2025, five positive Phase 3 readouts, and the first global approval for sotagliflozin.
Viatris Inc. (VTRS) submitted a Form 144 reporting a proposed sale of 7,032 common shares with an aggregate market value of $72,044.59. The filing lists 1,165,872,127 shares outstanding and an approximate sale date of 09/11/2025 on NASDAQ. The securities were acquired on 03/04/2025 as restricted stock units that vested and are described as a compensatory payment. The broker/contact block lists an address for Viatris Inc. in Canonsburg, PA. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Insider grant reported: Viatris Inc. director and officer Andrew Enrietti received a grant of 75,401 restricted stock units (RSUs) on 08/15/2025. Each RSU represents the right to one share of Viatris common stock. The RSUs vest in three annual tranches: 25,134 shares vest on 08/15/2026, 25,133 on 08/15/2027, and 25,134 on 08/15/2028. Following the grant, Enrietti beneficially owns 75,401 shares reported as direct ownership. The Form 4 was signed by power of attorney on 08/19/2025 and lists Enrietti's title as Chief Administrative and Transformation Officer.
Viatris Inc. (VTRS) Form 3 reports that Andrew Enrietti, identified as an officer and director-level executive (Chief Administrative and Transformation Officer), beneficially owns 130,000 shares of common stock directly and holds multiple employee equity awards. The filing lists vested stock options exercisable between 2026 and 2030 covering 11,697 options and several restricted stock unit grants and dividend equivalent units totaling 99,237 underlying shares scheduled to vest on specified dates between 2026 and 2028.
Scott A. Smith, who serves as both Chief Executive Officer and a director of Viatris Inc. (VTRS), acquired 22,000 shares of the company’s common stock on 08/12/2025 at a weighted average price of $9.9882 per share. After the purchase, the reporting person directly beneficially owned 314,807 shares.
The filing notes the acquisition price represents a weighted average of purchases in a range from $9.68 to $10.12; the reporting person offered to provide detailed per-price quantities on request. This Form 4 discloses an insider purchase by the CEO, showing an increase in his direct holdings without any derivative transactions reported.
Viatris director David S. Simmons reported the acquisition of 22,820 restricted stock units (RSUs) with a transaction date of 08/11/2025. Each RSU represents the right to receive one share of Viatris common stock at a $0 conversion price, and the award is scheduled to vest on March 6, 2026, at which point the RSUs convert into common shares.
The Form 4 shows this as an insider equity award reported by a single reporting person and executed under a power of attorney. The filing documents an equity grant/vesting schedule rather than a sale or cash purchase.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
